Registered title, quoted from ClinicalTrials.gov
OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Nanfang Hospital; 7 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 8
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead sponsorNanfang Hospital南方医科大学南方医院GuangzhouHospital page
- Study siteFirst Affiliated Hospital of Guangzhou University of Chinese Medicine广州中医药大学第一附属医院GuangzhouHospital page
- Study siteFirst Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page
- Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
- Study siteGuangdong Provincial People's Hospital广东省人民医院GuangzhouHospital page
- Study siteShantou University Medical College hospitals汕头大学医学院附属医院ShantouHospital page
- Study siteSixth Affiliated Hospital of Sun Yat-sen University中山大学附属第六医院GuangzhouHospital page
- Study siteThird Xiangya Hospital中南大学湘雅三医院ChangshaHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT05450835, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 5
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (5 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Primary lesion is pathologically diagnosed as gastric adenocarcinoma;
Inclusion criterion 2
Confirmed stage IV (AJCC 8th) during surgery
Exclusion criterion 4
Preoperative performance status (ECOG, Eastern Cooperative Oncology Group) of 0 or 1;
Inclusion criterion 6
Women during pregnancy or breast-feeding;
Exclusion criterion 1
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05450835, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Aged 18-75 years;
- Primary lesion is pathologically diagnosed as gastric adenocarcinoma;
- Expected to live more than 1 year;
- Tumor located located in gastroesophageal junction (GEJ) involve esophagus no more than 2cm, or in the upper, upper to middle, or entire stomach, and intend to perform laparoscopic total gastrectomy with D2 lymphadenectomy
- No history of upper abdominal surgery (except for laparoscopic cholecystectomy);
- Preoperative performance status (ECOG, Eastern Cooperative Oncology Group) of 0 or 1;
- Preoperative ASA (American Society of Anesthesiologists) scoring: I-III;
- Without preoperative radiotherapy;
- Did not found metastasis preoperatively and intraoperatively;
- Sufficient organ functions;
- Written informed consent.
Exclusion Criteria:
- Women during pregnancy or breast-feeding;
- Body temperature ≥ 38 °C before surgery or infectious disease with a systemic therapy indicated;
- Severe mental disease;
- Confirmed stage IV (AJCC 8th) during surgery
- Severe respiratory disease;
- Severe hepatic and renal dysfunction;
- Unstable angina pectoris or history of myocardial infarction within 6 months;
- History of cerebral infarction or cerebral hemorrhage within 6 months;
- Gastric cancer complications (bleeding, perforation, obstruction) that requiring emergency surgery;
- Performing hyperthermic intraperitoneal chemotherapy (HIPEC) after surgery.
Quoted from ClinicalTrials.gov, NCT05450835, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT05450835, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.